Trial Profile

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 May 2026 According to a NKGen Biotech media release, the company announced the activation of three additional clinical trial sites in the United States for its ongoing Phase 2 study of troculeucel in moderate Alzheimer's disease. The new sites include Rutgers Health in Newark, New Jersey, Alzheimer's Disease Research Center in Albany, New York, and K2 Medical Research in Orlando, Florida.
14 May 2026 Planned End Date changed from 1 Jun 2026 to 1 Jun 2027.
14 May 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com